Cardiometabolic Disease Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Chronic/Congestive Heart Failure, Hypertension, Type II Diabetes, Obesity), By Treatment (ACE Inhibitors, Diuretics, Glucophage, Liposuction, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Region Forecast 2020-2031

Cardiometabolic Disease Market size was valued at US$ 124.98 billion in 2024 and is expected to reach US$ 162.26 billion by 2031, growing at a significant CAGR of 3.8% from 2025-2031. Some of the key factors influencing the market growth include growing demand for a healthy lifestyle as it a crucial for maintenance. Due to rapidly changing lifestyle, food habits and genetic predisposition, rising in the incidence of various diseases such as diabetes, high cholesterol, cardiovascular disease, hypertension and others. Additionally, increasing awareness and government initiatives on public healthcare will fuel the market growth. Huge demand for plants based nutritional products and treatment requires a combination of nourishing, behavioral, and drug treatments, wherein drugs act as an assistant to behavioral therapies. Additionally, increase in acceptance of dietary food supplements and technological advancement in biotechnology for launching new products boosting the market growth. However, lack of awareness among the aged population and lack of standard norms and regulations regarding the medical facilities are some of the factor hinder the market growth.

This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Key Developments:

• In Oct 2021, Boehringer Ingelheim and Eli Lilly and Company launched CRMSynced, a gamified teaching program that encourages healthcare providers to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) problems. Recent advancements in C-R-M treatment and standards have shifted the burden of care to all members of the patient care team, including primary care physicians, specialists, and advanced practice clinicians.
• In Nov 2021, Novo Nordisk acquired Dicerna Pharmaceuticals including the RNAi research technology platform. Dicerna's expertise in RNAi and oligonucleotide therapeutics, as well as its highly skilled employees, combined with Novo Nordisk's industry leadership in developing and commercializing medicines to treat serious chronic diseases, has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all of our stakeholders.